Iomeron

Iomeprol, the active ingredient in Iomeron, is an iodinated contrast media presented as a solution for injection for intra‑arterial, intrathecal, and intravenous use. It provides radiodense contrast that enhances X‑ray attenuation, allowing clearer visualization of vascular and tissue structures during diagnostic imaging procedures.

GNH USA supplies Iomeron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Customers benefit from reliable logistics and responsive technical support.

Iomeron, an iodinated contrast agent, enhances radiographic visualization in several imaging pathways. - Angiography: improves delineation of blood vessels by increasing X‑ray attenuation of intravascular iodine, allowing precise mapping of arterial and capillary networks. - Computed Tomography (CT) imaging: provides high‑contrast enhancement of soft tissues and vascular structures for diagnostic accuracy, especially in abdominal, thoracic and neuro‑cranial examinations. - Myelography: facilitates clear visualization of the spinal canal and nerve roots during contrast‑enhanced studies, improving detection of compressive lesions and disc herniations. - Venography: highlights venous anatomy, aiding in the assessment of thrombosis or vascular malformations, and supports planning of interventional procedures.

Iomeprol may be associated with a range of adverse reactions, most of which are mild, transient, and resolve spontaneously.

Common Side Effects: - Warmth or flushing sensation during injection, typically lasting a few seconds. - Metallic taste in the mouth, often reported immediately after administration. - Nausea or mild vomiting, which usually resolves without treatment.

Serious or Rare Side Effects: - Severe allergic reaction or anaphylaxis, presenting with rash, bronchospasm, or circulatory collapse. - Acute renal impairment in susceptible patients, indicated by rising serum creatinine after exposure. - Hypotension or cardiovascular collapse, requiring immediate monitoring and supportive care.

Patients should be observed for any of these reactions and managed according to clinical guidelines.

When using Iomeron, several precautionary measures help minimize risks and ensure optimal imaging outcomes. - Renal function assessment: evaluate serum creatinine and eGFR before administration in patients with known kidney disease. - Allergy screening: confirm absence of prior iodine or contrast media hypersensitivity and consider pre‑medication if risk exists. - Dose optimization: use the lowest effective volume to achieve adequate image contrast. - Vital sign monitoring: observe blood pressure and heart rate during and after injection, especially in high‑risk patients. - Thyroid considerations: avoid use in uncontrolled hyperthyroidism due to iodine load. - Store at ambient temperature: keep the solution in its original container, protect from light and moisture, and do not freeze.

Iomeron can interact with certain medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Metformin: risk of lactic acidosis if renal function declines after contrast exposure; discontinue metformin before and after procedure as advised. - Thyroid hormone therapy: excess iodine may alter hormone levels; monitor thyroid function tests closely. - Iodine‑containing drugs (e.g., amiodarone): may increase total iodine load and precipitate thyroid dysfunction.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate volume depletion and affect renal clearance of contrast. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can impair renal perfusion, increasing risk of contrast‑induced nephropathy. - ACE inhibitors or ARBs: may influence renal hemodynamics; consider temporary suspension around imaging.